Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study.

Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study.

Publication date: Mar 24, 2020

Circulating tumour cells (CTCs) from liquid biopsies provide an exceptional opportunity to obtain real-time tumour information and are under current investigation in several cancers, including cutaneous melanoma, but face significant drawbacks in terms of non-standardised methodology, low viable cell numbers and accuracy of CTC identification. In this pilot study, we report that chemosensitivity assays using liquid biopsy-derived metastatic melanoma (MM) CTCs, from 7 patients with stage IIIC, BRAF wild-type metastatic melanomas, localized exclusively to the pelvic region, un-eligible for immunotherapy and treated with melphalan hypoxic pelvic perfusion (HPP), is both feasible and useful in predicting response to therapy. Viable MM CTCs (>?5 cells/ml for all 7 blood samples), enriched by transient culture, were characterised in flow cytometry-based Annexin V-PE assays for chemosensitivity to several drugs.

Using melphalan as a standard, chemosensitivity cut-off values of?>?60% cell death, were predictive of patient RECIST 1.1 response to melphalan HPP therapy, associated with calculated 100% sensitivity, 66.67% specificity, 33.33% positive predictive, 100% negative predictive, and 71.43% accuracy values. We propose that the methodology in this study is both feasible and has potential value in predicting response to therapy, setting the stage for a larger study. Trial registration Clinical Trials.gov Identifier NCT01920516; date of trial registration: August 6, 2013.

Open Access PDF

Guadagni, S., Fiorentini, G., , Papasotiriou, Apostolou, P., Masedu, F., Sarti, D., Farina, A.R., Mackay, A.R., and Clementi, M. Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study. 26218. 2020 BMC Res Notes (13):1.

Concepts Keywords
Blood Recurrent cutaneous melanoma
BMC Locoregional pelvic metastases
BRAF Immunotherapy
Flow Cytometry Medicine
Hypoxic Clinical medicine
Immunotherapy Medical specialties
Melanoma Biopsy
Melanomas Oncology
Melphalan Specialty drugs
Metastases Interventional radiology
Metastatic Melanoma
Perfusion Metastasis
Tumour Liquid biopsy
Wild Type Melphalan
Circulating tumor cell

Semantics

Type Source Name
disease MESH biopsy
disease MESH metastases
disease MESH cancers
disease MESH melanoma
pathway KEGG Melanoma
drug DRUGBANK Melphalan
disease MESH death
pathway REACTOME Reproduction
drug DRUGBANK Diphencyprone
drug DRUGBANK Imiquimod
drug DRUGBANK Talimogene laherparepvec
disease MESH hypoxia
drug DRUGBANK Dabrafenib
drug DRUGBANK Trametinib
drug DRUGBANK Pembrolizumab
drug DRUGBANK Ipilimumab
drug DRUGBANK Nivolumab
disease MESH viral infections
drug DRUGBANK Trestolone
disease MESH immuno
disease MESH Hepatitis
disease MESH infection
drug DRUGBANK Sofosbuvir
drug DRUGBANK Daclatasvir
disease MESH separation
drug DRUGBANK Platinum
drug DRUGBANK Paclitaxel
drug DRUGBANK Bleomycin
disease MESH circulating tumor cells
drug DRUGBANK Fluorouracil
drug DRUGBANK Gemcitabine
drug DRUGBANK Epirubicin
drug DRUGBANK Etoposide
drug DRUGBANK Carboplatin
drug DRUGBANK Cisplatin
drug DRUGBANK Oxaliplatin
drug DRUGBANK Docetaxel
drug DRUGBANK Vinorelbine
drug DRUGBANK Topotecan
drug DRUGBANK Irinotecan
disease MESH relapse
disease MESH ovarian cancers
disease MESH sarcoma
drug DRUGBANK Formaldehyde
drug DRUGBANK Edetic Acid
drug DRUGBANK Ethylenediamine
drug DRUGBANK L-Tyrosine
disease MESH Growth
drug DRUGBANK Gold
drug DRUGBANK Coenzyme M
drug DRUGBANK Honey
disease MESH rectal cancer
disease MESH uveal melanoma
drug DRUGBANK Oleandrin
disease MESH epithelial ovarian cancer
drug DRUGBANK Indoleacetic acid

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *